Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 531 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020:11 de julio. [Ref.ID 103688]
2. Cita con resumen
3. Cita con resumen
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]
4. Cita con resumen
Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]
5.Tiene citas relacionadas Cita con resumen
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 — Preliminary report. N Engl J Med 2020:22 de mayo. [Ref.ID 103631]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:29 de abril. [Ref.ID 103630]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of covid-19. N Engl J Med 2020;382:18 de junio. [Ref.ID 103603]
10. Cita con resumen
Salvador R. Los laboratorios reconvierten sus fábricas para combatir el coronavirus. La Vanguardia 2020:13 de abril. [Ref.ID 103582]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F-X, Nicastri E, Oda R, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020:10 de abril. [Ref.ID 103581]
12.Enlace a cita original Cita con resumen
Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, Mandourah Y, Almekhlafi GA, Almaani M, Bshabshe A, Finfer S, Arshad Z, Khalid I, Mehta Y, Gaur A, Hawa H, Buscher H, Lababidi H, Al Aithan A, Abdukahil SAI, Jose J, Afesh LY, Al-Dawood A, for the Saudi Critical Care Trials Group. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. N Engl J Med 2019;380:4 de abril. [Ref.ID 103074]
13.Enlace a cita original Cita con resumen
Girard TD , Exline MC , Carson SS , Hough CL , Rock P , Gong MN , Douglas IS , Malhotra A , Owens RL , Feinstein DJ , Khan B , Pisani MA , Hyzy RC , Schmidt GA , Schweickert WD , Hite RD , Bowton DL , Masica AL , Thompson JL , Chandrasekhar R , Pun BT , Strength C , Boehm LM , Jackson JC , Pandharipande PP , Brummel NE , Hughes CG , Patel MB , Stollings JL , Bernard GR , Dittus RS , Ely EW , for the MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in vritical illness. N Engl J Med 2018;379:22 de octubre. [Ref.ID 102838]
14. Cita con resumen
Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506-16. [Ref.ID 102735]
16. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
18. Cita con resumen
Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, Brealey D, Nutt CL, McNamee JJ, Reschreiter H, Breen A, Liu KD, Ashby D. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016;375:1638-48. [Ref.ID 100914]
19.Tiene citas relacionadas Cita con resumen
Timsit J-F, Azoulay E, Schwebel C, Charles P-E, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet J-L, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou J-C, Foucrier A, Allaouchiche B, Das V, Gangneux J-P, Ruckly S, Maubon D, Jullien V, Wolff M, for the EMPIRICUS Trial Group. Empirical micafungin treatment and survival whithout invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure. The EMPIRICUS randomized clinical trial. JAMA 2016;316:1555-64. [Ref.ID 100904]
20.Tiene citas relacionadas
Siddharthan T, Karakousis PC, Checkley W. Empiral antifungal therapy in critically ill patients with sepsis. Another case of less is more in the ICU. JAMA 2016;316:1549-50. [Ref.ID 100903]
Seleccionar todas
 
 1 a 20 de 531 siguiente >>